Enantioselective Synthesis of a Key Intermediate toward Dragmacidin E via Base-Promoted Olefin Isomerization–Ir-Catalyzed Asymmetric Hydrogenation Sequence
Chemical and Pharmaceutical Bulletin · 2025
DOI: 10.1248/cpb.c25-00703 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical and Pharmaceutical Bulletin, 2025. Verfasst von Noa Takahashi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8675, Japan. Hauptthemen laut MEDLINE: Alkenes, Iridium. Die Arbeit nennt 18 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8675, Japan.
Zitieren
APA
Takahashi, N., Harada, S., & Nemoto, T. (2025). Enantioselective Synthesis of a Key Intermediate toward Dragmacidin E via Base-Promoted Olefin Isomerization–Ir-Catalyzed Asymmetric Hydrogenation Sequence. Chemical and Pharmaceutical Bulletin. https://doi.org/10.1248/cpb.c25-00703
Vancouver
Takahashi N, Harada S, Nemoto T. Enantioselective Synthesis of a Key Intermediate toward Dragmacidin E via Base-Promoted Olefin Isomerization–Ir-Catalyzed Asymmetric Hydrogenation Sequence. Chemical and Pharmaceutical Bulletin. 2025. doi:10.1248/cpb.c25-00703
BibTeX
@article{Takahashi2025,
author = {Takahashi, Noa and Harada, Shingo and Nemoto, Tetsuhiro},
title = {Enantioselective Synthesis of a Key Intermediate toward Dragmacidin E via Base-Promoted Olefin Isomerization–Ir-Catalyzed Asymmetric Hydrogenation Sequence},
journal = {Chemical and Pharmaceutical Bulletin},
year = {2025},
doi = {10.1248/cpb.c25-00703}
}
EUVIMED